Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Preselective gene therapy for Fabry disease.

G Qin1, T Takenaka, K Telsch

  • 1Department of Medicine, University of Illinois, Chicago, IL 60607, USA.

Proceedings of the National Academy of Sciences of the United States of America
|March 15, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FGFR1-amplified colorectal cancer: a distinct prognostic subtype identified through integrated genomic and immunohistochemical profiling.

ESMO open·2025
Same author

Correction to "Construction of Ultrastable Ultrathin Black Phosphorus Nanodisks Hybridized with Fe<sub>3</sub>O<sub>4</sub> Nanoclusters and Iron (V)-Oxo Complex for Efficient Potassium Storage".

Advanced materials (Deerfield Beach, Fla.)·2025
Same author

Evaluation of first-trimester ultrasound screening strategy for fetal congenital heart disease.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2025
Same author

[A comparative study for the efficacies of transaxillary non-inflatable endoscopic surgery versus traditional surgery for papillary thyroid carcinoma].

Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery·2023
Same author

Laparoscopic radical resection for rectal cancer in a patient with uncorrected truncus arteriosus type IV: A case report.

Revista espanola de anestesiologia y reanimacion·2023
Same author

The performance of left/right adrenal volume ratio and volume difference in predicting unilateral primary aldosteronism.

Journal of endocrinological investigation·2022
Same journal

Chemotactic self-organization captures the dynamics of mammalian hair follicle patterning.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same journal

Tomographic imaging of superconducting order using particle-hole interference.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same journal

Inhibitory potential of autologous neutralizing antibodies sets quantitative limits on the rebound-competent HIV-1 reservoir.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same journal

Inferring epidemiological parameters under an infectious phylogeography model with visitor dynamics.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same journal

Analytical modeling for suction cup designs for skin-interfaced wearable devices.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same journal

Improving cell-free metabolism through direct integration of artificial respiratory chains.

Proceedings of the National Academy of Sciences of the United States of America·2026
See all related articles

Gene therapy for Fabry disease shows improved efficiency using a novel vector. This approach enhances alpha-galactosidase A enzyme activity in hematopoietic stem cells, offering potential for better treatment outcomes.

Area of Science:

  • Biochemistry
  • Genetics
  • Hematology

Background:

  • Fabry disease is a genetic lipid storage disorder caused by alpha-galactosidase A (alpha-gal A) deficiency.
  • Previous studies demonstrated ex vivo gene therapy using hematopoietic cells for Fabry disease in mice.

Purpose of the Study:

  • To improve the efficiency of ex vivo gene therapy for Fabry disease.
  • To evaluate a novel bicistronic retroviral vector co-expressing alpha-gal A and huCD25 for enhanced gene correction.

Main Methods:

  • Developed a bicistronic retroviral vector for co-expression of alpha-gal A and huCD25.
  • Utilized huCD25 as a selectable marker for immunoenrichment (preselection) of transduced cells.
  • Assessed gene therapy efficacy in a mouse model of Fabry disease, including primary and secondary transplantations.

Related Experiment Videos

Main Results:

  • Co-expression of huCD25 enabled efficient preselection of transduced human and murine cells, enhancing alpha-gal A activity.
  • Preselection of transduced Fabry mouse bone marrow cells increased gene-corrected hematopoietic cells in circulation.
  • Improved in vivo alpha-gal A enzyme activity in plasma and organs for over 6 months post-transplantation.

Conclusions:

  • A huCD25-based preselection strategy significantly enhances ex vivo gene therapy for Fabry disease.
  • This approach holds promise for improving the clinical utility of hematopoietic stem/progenitor cell gene therapy for Fabry disease and other genetic disorders.